Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSOTCMKTS:ASPCFNASDAQ:NRBONYSEAMERICAN:NTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.41-0.6%$3.50$3.96▼$12.00$6.11M1.557,305 shs2,601 shsASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/ANRBONeuroBo Pharmaceuticals$0.66+1.8%$0.72$2.08▼$5.16$20.33M-0.2639,197 shs59,409 shsNTNNTN Buzztime$1.84-0.5%$0.80$0.94▼$7.76$5.48M0.721.63 million shs21,355 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+0.88%+3.16%+1.78%+16.51%-22.22%ASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NRBONeuroBo Pharmaceuticals+1.06%-3.19%-0.03%-57.79%-86.11%NTNNTN Buzztime0.00%-7.07%+744.04%+863.35%-4.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AASPCFAcerus Pharmaceuticals 0.00N/AN/AN/ANRBONeuroBo Pharmaceuticals 0.00N/AN/AN/ANTNNTN Buzztime 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.58N/AN/A$14.99 per share0.23ASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/ANTNNTN Buzztime$19.81M0.28$0.42 per share4.38$1.76 per share1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)ASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)NTNNTN Buzztime-$2.05MN/AN/A∞N/A-61.42%-162.54%-49.94%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93ASPCFAcerus PharmaceuticalsN/A0.670.34NRBONeuroBo PharmaceuticalsN/A2.412.41NTNNTN Buzztime3.300.950.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%ASPCFAcerus PharmaceuticalsN/ANRBONeuroBo Pharmaceuticals1.37%NTNNTN Buzztime6.31%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%ASPCFAcerus PharmaceuticalsN/ANRBONeuroBo Pharmaceuticals1.05%NTNNTN Buzztime24.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableNTNNTN Buzztime192.98 millionN/ANot OptionableASPCF, AEZS, NTN, and NRBO HeadlinesRecent News About These CompaniesEterna Therapeutics sets annual meeting date, opens nominationsFebruary 13, 2025 | msn.comBryant FBLA students to host yard sale, Big Blue Market on April 20April 5, 2024 | bentoncourier.comBThe Petri Dish: Boston biotech scores FDA approval, antiviral maker stops 3 studiesDecember 28, 2023 | bizjournals.comExclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50MMay 2, 2023 | bizjournals.comBrooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsApril 15, 2022 | ca.finance.yahoo.comA list of mental health startups in the Pacific Northwest, as pandemic fuels growth for sectorMarch 23, 2022 | geekwire.comGMy Buzzcard LoginJanuary 13, 2022 | c21media.netCTop 10 Penny Stocks of 2017October 26, 2021 | finance.yahoo.comEveryone from pharma giants to startup biotechs wants in on the hottest way to develop drugsOctober 6, 2021 | msn.comDemocrats push to retool health care programs for millionsSeptember 20, 2021 | sandiegouniontribune.comSSporcle Events: A New BeginningAugust 31, 2021 | sporcle.comSMedia Sentiment Over TimeASPCF, AEZS, NTN, and NRBO Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.41 -0.02 (-0.58%) As of 07/2/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Acerus Pharmaceuticals OTCMKTS:ASPCF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.66 +0.01 (+1.82%) As of 07/2/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.NTN Buzztime NYSEAMERICAN:NTN$1.84 -0.01 (-0.54%) As of 06/30/2025NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
